In the 2022/2023 business year, we spent EUR 48 million on research and development

The first and only fixed-dose combination of atorvastatin and esetimibe in Russia

Egis launches in Russia a product with fixed-doses of atorvastatin and ezetimibe in one capsule for the treatment of hypercholesterolemia [1]. Fixed-dose combination (FDC) developed by Egis will increase adherence in patients who take atorvastatin and ezetimibe separately, and a single dose per day should significantly simplify the drug therapy regimen.


Egis has launched a new ezetimibe of European quality to reduce of cardiovascular disease risks

Egis has launched to the Russian market a new ezetimibe of European quality that helps to achieve the target level of low-density lipoprotein cholesterol in cases where the statin therapy is not enough. The drug is produced in Hungary (EU) in accordance with Good Manufacturing Practices (GMP). At the same time, the new product is more affordable compared to the original ezetimibe [6], which ensures its high attractiveness for Russian doctors and their patients. The product has already been registered in Russia and sold in Russian pharmacies from October 2021.


Egis Inaugurates Two New Plants in Körmend

Two technology-intensive developments, carried out with state subsidies, were completed at Egis Pharmaceuticals PLC’s Körmend site (Hungary). The investments were inaugurated by Péter Szijjártó, Minister of Foreign Affairs and Trade, and by the company’s CEO, Dr. István Hodász on 15 October.  In addition to a new packaging plant, Egis has also established a plant with special knowledge and technology requirements, typically suitable to manufacture oncology products.  Thus, Egis is now able to implement all value-creating processes within the field of oncology, from development to active ingredient and finished product manufacturing.


Egis launches the first in Russia drug combination treatment for lowering cholesterol levels¹

Hungarian-based Egis Pharmaceuticals PLC launch in Russia the first fixed drug combination of two lipid-lowering agents: rosuvastatin and ezetimibe.

WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox